Adjunctive treatment in septic shock: What's next?

Presse Medicale

Volumn 45, Issue 4, 2016, Pages e105-e109

  Annane, Djillali ^a  

^a LABORATOIRE DES SCIENCES DU CLIMAT ET DE L ENVIRONNEMENT   (France)

Author keywords

[No Author keywords available]

Indexed keywords

3 (2,4 DIMETHOXYBENZYLIDENE)ANABASEINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CORTICOSTEROID; DOPAMINE; ESMOLOL; FLUDROCORTISONE; GAMMA INTERFERON; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; HYDROCORTISONE; IMMUNOGLOBULIN; MILRINONE; NORADRENALIN; PROGRAMMED DEATH 1 LIGAND 2; PROPRANOLOL; SELEPRESSIN; THYMOSIN ALPHA1; VASOPRESSIN;

BACTERIAL CLEARANCE; CARDIOGENIC SHOCK; CHOLINERGIC SYSTEM; CYTOKINE PRODUCTION; HEART ARREST; HUMAN; HYPERGLYCEMIA; HYPERNATREMIA; IMMUNOMODULATION; INFECTION PREVENTION; INTENSIVE CARE; LENGTH OF STAY; LOW DRUG DOSE; LUNG INFECTION; MORTALITY; NONHUMAN; SECONDARY INFECTION; SEPTIC SHOCK; SEQUENTIAL ORGAN FAILURE ASSESSMENT SCORE; SHORT SURVEY; SURVIVAL RATE; ADJUVANT CHEMOTHERAPY; SHOCK, SEPTIC;

CHEMOTHERAPY, ADJUVANT; HUMANS; SHOCK, SEPTIC;

EID: 84963998005     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2016.03.004     Document Type: Short Survey

References (54)

1. Moss M. Epidemiology of sepsis: race, sex, and chronic alcohol abuse. Clin Infect Dis 2005, 41:S490-S497.
2. Annane D., Aegerter P., Jars-Guincestre M.C., Guidet B. Current epidemiology of septic shock: the CUB-Rea Network. Am J Respir Crit Care Med 2003, 1687:165-172.
3. Iwashyna T.J., Ely A.W., Smith D.M., Langa K.M. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA 2010, 304:1787-1794.
4. Annane D., Sharshar T. Cognitive decline after sepsis. Lancet Respir Med 2015, 3:61-69.
5. Dellinger R.P., Levy M.M., Rhodes A., Annane D., Gerlach H., Opal S.M., et al. Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock, 2012. Intensive Care Med 2013, 39:165-228.
6. Annane D., Bellissant E., Bollaert P.E., Briegel J., Keh D., Kupfer Y. Corticosteroids for treating sepsis. Cochrane Database Syst Rev 2015, 12:CD002243. http://www.ncbi.nlm.nih.gov/pubmed/26633262.
7. Venkatesh B., Myburgh J., Finfer S., Webb S.A., Cohen J., Bellomo R., et al. The ADRENAL study protocol: adjunctive corticosteroid treatment in critically ill patients with septic shock. Crit Care Resusc 2013, 15:83-88.
8. Sharshar T., Blanchard A., Paillard M., Raphael J.C., Gajdos P., Annane D. Circulating vasopressin levels in septic shock. Crit Care Med 2003, 31:1752-1758.
9. Sonneville R., Guidoux C., Barrett L., Viltart O., Mattot V., Polito A., et al. Vasopressin synthesis by the magnocellular neurons is different in the supraoptic nucleus and in the paraventricular nucleus in human and experimental septic shock. Brain Pathol 2010, 20:613-622.
10. Siami S., Bailly-Salin J., Polito A., Porcher R., Blanchard A., Haymann J.P., et al. Osmoregulation of vasopressin secretion is altered in the postacute phase of septic shock. Crit Care Med 2010, 38:1962-1969.
11. Siami S., Polito A., Porcher R., Hissem T., Blanchard A., Boucly C., et al. Thirst perception and osmoregulation of vasopressin secretion are altered during recovery from septic shock. PLoS One 2013, 8(11):e80190.
12. Polito A., Parisini E., Ricci Z., Picardo S., Annane D. Vasopressin for treatment of vasodilatory shock: an ESICM systematic review and meta-analysis. Intensive Care Med 2012, 38:9-19.
13. Oba Y., Lone N.A. Mortality benefit of vasopressor and inotropic agents in septic shock: a Bayesian network meta-analysis of randomized controlled trials. J Crit Care 2014, 29:706-710.
14. Gordon A.C., Mason A.J., Perkins G.D., Ashby D., Brett S.J. Protocol for a randomised controlled trial of VAsopressin versus Noradrenaline as Initial therapy in Septic sHock (VANISH). BMJ Open 2014, 4(7):e005866.
15. [accessed on October 25 2015]. http://www.esicm.org/news-article/LIVES-2015-ENEWS-RESULTS-Vasopressin-SEPTIC-SHOCK-GORDON.
16. Rehberg S., Yamamoto Y., Sousse L., Bartha E., Jonkam C., Hasselbach A.K., et al. Selective V(1a) agonism attenuates vascular dysfunction and fluid accumulation in ovine severe sepsis. Am J Physiol Heart Circ Physiol 2012, 303:H1245-H1254.
17. Maybauer M.O., Maybauer D.M., Enkhbaatar P., Laporte R., Wiśniewska H., Traber L.D., et al. The selective vasopressin type 1a receptor agonist selepressin (FE 202158) blocks vascular leak in ovine severe sepsis. Crit Care Med 2014, 42:e525-e533.
18. Grisanti L.A., Evanson J., Marchus E., Jorissen H., Woster A.P., DeKrey W., et al. Pro-inflammatory responses in human monocytes are beta1-adrenergic receptor subtype dependent. Mol Immunol 2010, 47:1244-1254.
19. Scanzano A., Cosentino M. Adrenergic regulation of innate immunity: a review. Front Pharmacol 2015, 6:171.
20. Berk J.L., Hagen J.F., Beyer W.H., Gerber M.J., Dochat G.R. The treatment of endotoxin shock by beta-adrenergic blockade. Ann Surg 1969, 169:74-81.
21. Oberbeck R., Schmitz D., Wilsenack K., Schüler M., Pehle B., Schedlowski M., et al. Adrenergic modulation of survival and cellular immune functions during polymicrobial sepsis. Neuroimmunomodulation 2004, 11:214-223.
22. Suzuki T., Morisaki H., Serita R., Yamamoto M., Kotake Y., Ishizaka A., et al. Infusion of the beta-adrenergic blocker esmolol attenuates myocardial dysfunction in septic rats. Crit Care Med 2005, 33:2294-2301.
23. Ackland G.L., Yao S.T., Rudiger A., Dyson A., Stidwill R., Poputnikov D., et al. Cardioprotection, attenuated systemic inflammation, and survival benefit of beta1- adrenoceptor blockade in severe sepsis in rats. Crit Care Med 2010, 38:388-394.
24. Kimmoun A., Louis H., Al Kattani N., Delemazure J., Dessales N., Wei C., et al. β1-Adrenergic inhibition improves cardiac and vascular function in experimental septic shock. Crit Care Med 2015, 43:e332-e340.
25. Aboab J., Sebille V., Jourdain M., Mangalaboyi J., Gharbi M., Mansart A., et al. Effects of esmolol on systemic and pulmonary hemodynamics and on oxygenation in pigs with hypodynamic endotoxin shock. Intensive Care Med 2011, 37:1344-1351.
26. Gore D.C., Wolfe R.R. Hemodynamic and metabolic effects of selective beta1-adrenergic blockade during sepsis. Surgery 2006, 139:686-694.
27. Morelli A., Ertmer C., Westphal M., Rehberg S., Kampmeier T., Ligges S., et al. Effect of heart rate control with esmolol on hemodynamic and clinical outcomes in patients with septic shock: a randomized clinical trial. JAMA 2013, 310:1683-1691.
28. Wang Z., Wu Q., Nie X., Guo J., Yang C. Combination therapy with milrinone and esmolol for heart protection in patients with severe sepsis: a prospective, randomized trial. Clin Drug Investig 2015.
29. Borovikova L.V., Ivanova S., Zhang M., Yang H., Botchkina G.I., Watkins L.R., et al. Vagus nerve stimulation attenuates the systemic inflammatory response to endotoxin. Nature 2000, 405:458-462.
30. Wang H., Yu M., Ochani M., Amella C.A., Tanovic M., Susarla S., et al. Nicotinic acetylcholine receptor α7 subunit is an essential regulator of inflammation. Nature 2003, 421:384-387.
31. Huston J.M., Gallowitsch-Puerta M., Ochani M., Ochani K., Yuan R., Rosas-Ballina M., et al. Transcutaneous vagus nerve stimulation reduces serum high mobility group box 1 levels and improves survival in murine sepsis. Crit Care Med 2007, 35:2762-2768.
32. Pavlov V.A., Ochani M., Yang L.H., Gallowitsch-Puerta M., Ochani K., Lin X., et al. Selective alpha7-nicotinic acetylcholine receptor agonist GTS-21 improves survival in murine endotoxemia and severe sepsis. Crit Care Med 2007, 35:1139-1144.
33. Alejandria M.M., Lansang M.A., Dans L.F., Mantaring J.B. Intravenous immunoglobulin for treating sepsis, severe sepsis and septic shock. Cochrane Database Syst Rev 2013, 9. [CD001090].
34. Van Dissel J.T., van Langevelde P., Westendorp R.G., Kwappenberg K., Frölich M. Anti-inflammatory cytokine profile and mortality in febrile patients. Lancet 1998, 351:950-953.
35. Lang J.D., Matute-Bello G. Lymphocytes, apoptosis and sepsis: making the jump from mice to humans. Crit Care 2009, 13:109.
36. Guérin E., Orabona M., Raquil M.A., Giraudeau B., Bellier R., Gibot S., et al. Circulating immature granulocytes with T-cell killing functions predict sepsis deterioration. Crit Care Med 2014, 42:2007-2018.
37. Monneret G., Venet F. Monocyte HLA-DR in sepsis: shall we stop following the flow?. Crit Care 2014, 18:102.
38. Limaye A.P., Kirby K.A., Rubenfeld G.D., Leisenring W.M., Bulger E.M., Neff M.J., et al. Cytomegalovirus reactivation in critically ill immunocompetent patients. JAMA 2008, 300:413-422.
39. Hall M.W., Geyer S.M., Guo C.Y., Panoskaltsis-Mortari A., Jouvet P., Ferdinands J., et al. Innate immune function and mortality in critically ill children with influenza: a multicenter study. Crit Care Med 2013, 41:224-236.
40. Boomer J.S., To K., Chang K.C., Takasu O., Osborne D.F., Walton A.H., et al. Immunosuppression in patients who die of sepsis and multiple organ failure. JAMA 2011, 306:2594-2605.
41. Döcke W.D., Randow F., Syrbe U., Krausch D., Asadullah K., Reinke P., et al. Monocyte deactivation in septic patients: restoration by IFNg treatment. Nature Med 1997, 3:678-681.
42. Miles R.H., Paxton T.P., Dries D.J., Gamelli R.L. Interferon-gamma increases mortality following cecal ligation and puncture. J Trauma 1994, 36:607-611.
43. Bo L., Wang F., Zhu J., Li J., Deng X. Granulocyte-colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) for sepsis: a meta-analysis. Crit Care 2011, 15:R58.
44. Venet F., Foray A.P., Villars-Méchin A., Malcus C., Poitevin-Later F., et al. IL-7 restores lymphocyte functions in septic patients. J Immunol 2012, 189:5073-5081.
45. Ostatin A., Paltsev A., Leplina O., Shevela Y., Chernykh H. The experience of surgical infections treatment with extracorporal immunotherapy. Medicinskaya Immunol 2000, 2:43-51.
46. Wan J., Shan Y., Shan H., Li G., Wang T., Guan J., et al. Thymosin-alpha1 promotes the apoptosis of regulatory T cells and survival rate in septic mice. Front Biosci (Landmark Ed) 2011, 16:3004-3013.
47. Li C., Bo L., Liu Q., Jin F. Thymosin alpha1 based immunomodulatory therapy for sepsis: a systematic review and meta-analysis. Int J Infect Dis 2015, 33:90-96.
48. Zhang Y., Zhou Y., Lou J., Li J., Bo L., Zhu K., et al. PD-L1 blockade improves survival in experimental sepsis by inhibiting lymphocyte apoptosis and reversing monocyte dysfunction. Crit Care 2010, 14:R220.
49. Zhu W., Bao R., Fan X., Tao T., Zhu J., Wang J., et al. PD-L1 blockade attenuated sepsis-induced liver injury in a mouse cecal ligation and puncture model. Mediators Inflamm 2013, 2013:361501.
50. Mansur A., Hinz J., Hillebrecht B., Bergmann I., Popov A.F., Ghadimi M., et al. Ninety-day survival rate of patients with sepsis relates to programmed cell death 1 genetic polymorphism rs11568821. J Investig Med 2014, 62:638-643.
51. Chang K., Svabek C., Vazquez-Guillamet C., Sato B., Rasche D., Wilson S., et al. Targeting the programmed cell death 1: programmed cell death ligand 1 pathway reverses T cell exhaustion in patients with sepsis. Crit Care 2014, 18:R3.
52. Cavaillon J.M., Eisen D., Annane D. Is boosting the immune system in sepsis appropriate?. Crit Care 2014, 18:216.
53. Hara Y., Shimomura Y., Nakamura T., Kuriyama N., Yamashita C., Kato Y., et al. Novel blood purification system for regulating excessive immune reactions in severe sepsis and septic shock: an ex vivo pilot study. Ther Apher Dial 2015, 19:308-315.
54. Spite M., Norling L.V., Summers L., Yang R., Cooper D., Petasis N.A., et al. Resolvin D2 is a potent regulator of leukocytes and controls microbial sepsis. Nature 2009, 461:1287-1291.